174 related articles for article (PubMed ID: 35927359)
21. Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy.
Matsuo M; Yasumatsu R; Masuda M; Toh S; Wakasaki T; Hashimoto K; Jiromaru R; Manako T; Nakagawa T
In Vivo; 2022; 36(2):907-917. PubMed ID: 35241549
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of preoperative lymphocyte-monocyte ratio in patients with resectable esophageal squamous cell carcinoma.
Han LH; Jia YB; Song QX; Wang JB; Wang NN; Cheng YF
Asian Pac J Cancer Prev; 2015; 16(6):2245-50. PubMed ID: 25824745
[TBL] [Abstract][Full Text] [Related]
23. Development and Validation of a New Integrative Score Based on Various Systemic Inflammatory and Nutritional Indicators in Predicting Prognosis in Patients With Resectable Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study.
Feng JF; Wang L; Chen QX; Yang X
Cancer Control; 2022; 29():10732748221091394. PubMed ID: 35410489
[TBL] [Abstract][Full Text] [Related]
24. The status of perineural invasion predicts the outcomes of postoperative radiotherapy in locally advanced esophageal squamous cell carcinoma.
Ning ZH; Zhao W; Li XD; Chen LJ; Xu B; Gu WD; Shao YJ; Xu Y; Huang J; Pei HL; Jiang JT
Int J Clin Exp Pathol; 2015; 8(6):6881-90. PubMed ID: 26261575
[TBL] [Abstract][Full Text] [Related]
25. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Shirakawa T; Kato K; Nagashima K; Nishikawa A; Sawada R; Takahashi N; Shoji H; Sasaki Y; Honma Y; Iwasa S; Takashima A; Okita N; Hamaguchi T; Yamada Y; Shimada Y
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1207-15. PubMed ID: 25267597
[TBL] [Abstract][Full Text] [Related]
26. A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma.
Tang Y; Ou Z; Yao Z; Qiao G
Medicine (Baltimore); 2019 Oct; 98(40):e17164. PubMed ID: 31577707
[TBL] [Abstract][Full Text] [Related]
27. Neutrophil-to-lymphocyte ratio and C-reactive protein-to-albumin ratio as prognostic factors for unresectable advanced or recurrent gastric cancer.
Namikawa T; Shimizu S; Yokota K; Tanioka N; Munekage M; Uemura S; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
Langenbecks Arch Surg; 2022 Mar; 407(2):609-621. PubMed ID: 34652563
[TBL] [Abstract][Full Text] [Related]
28. Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy.
Nomura M; Hosokai T; Tamaoki M; Yokoyama A; Matsumoto S; Muto M
Esophagus; 2023 Oct; 20(4):722-731. PubMed ID: 37093536
[TBL] [Abstract][Full Text] [Related]
29. A novel inflammation-based prognostic score for patients with esophageal squamous cell carcinoma: the c-reactive protein/prognostic nutritional index ratio.
Chen S; Yang X; Feng JF
Oncotarget; 2016 Sep; 7(38):62123-62132. PubMed ID: 27557504
[TBL] [Abstract][Full Text] [Related]
30. Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan.
Harada K; Yamamoto S; Kato K
Expert Opin Biol Ther; 2022 Nov; 22(11):1333-1338. PubMed ID: 36266954
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of the C-reactive protein-to-albumin ratio for the prognosis of patients with esophageal squamous cell carcinoma.
Kunizaki M; Tominaga T; Wakata K; Miyazaki T; Matsumoto K; Sumida Y; Hidaka S; Yamasaki T; Yasutake T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
Mol Clin Oncol; 2018 Feb; 8(2):370-374. PubMed ID: 29435305
[TBL] [Abstract][Full Text] [Related]
32. Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study.
Mori Y; Kikuchi O; Horimatsu T; Hara H; Hironaka S; Kojima T; Kato K; Tsushima T; Ishihara R; Mukai K; Uozumi R; Tada H; Kasai H; Kawaguchi A; Muto M
Esophagus; 2022 Jul; 19(3):444-451. PubMed ID: 35050435
[TBL] [Abstract][Full Text] [Related]
33. Prechemotherapy neutrophil : lymphocyte ratio is superior to the platelet : lymphocyte ratio as a prognostic indicator for locally advanced esophageal squamous cell cancer treated with neoadjuvant chemotherapy.
Ji WH; Jiang YH; Ji YL; Li B; Mao WM
Dis Esophagus; 2016 Jul; 29(5):403-11. PubMed ID: 25625421
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina.
Martin C; Lupinacci L; Perazzo F; Bas C; Carranza O; Puparelli C; Kowalyszyn R; Magri I; Varela M; Richardet E; Vera K; Foglia S; Jerez I; Aman E; Martinengo G; Batagelj E; Dri A; Pilnik N; Roa GM; Mando P; Tsou F; Recondo G; Cayol F; Flores M; Sena S; Bagnes C; Waisberg FD; Minatta JN; Rizzo M
Clin Lung Cancer; 2020 Sep; 21(5):e380-e387. PubMed ID: 32213298
[TBL] [Abstract][Full Text] [Related]
35. Nivolumab for the treatment of esophageal cancer.
Mikuni H; Yamamoto S; Kato K
Expert Opin Biol Ther; 2021 Jun; 21(6):697-703. PubMed ID: 33736560
[No Abstract] [Full Text] [Related]
36. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
Kato K; Doki Y; Ogata T; Motoyama S; Kawakami H; Ueno M; Kojima T; Shirakawa Y; Okada M; Ishihara R; Kubota Y; Amaya-Chanaga C; Chen T; Matsumura Y; Kitagawa Y
Esophagus; 2023 Apr; 20(2):291-301. PubMed ID: 36401133
[TBL] [Abstract][Full Text] [Related]
37. Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Otsuki S; Hori R; Shinohara S; Kojima T; Tamaki H; Asato R; Kitamura M; Ichimaru K; Kitani Y; Kumabe Y; Honda K; Tsujimura T; Harada H; Ushiro K; Omori K
Auris Nasus Larynx; 2022 Oct; 49(5):834-844. PubMed ID: 35232636
[TBL] [Abstract][Full Text] [Related]
38. The usefulness of the total metabolic tumor volume for predicting the postoperative recurrence of thoracic esophageal squamous cell carcinoma.
Kaida H; Yasuda T; Shiraishi O; Kato H; Kimura Y; Hanaoka K; Yamada M; Matsukubo Y; Tsurusaki M; Kitajima K; Hattori S; Ishii K
BMC Cancer; 2022 Nov; 22(1):1176. PubMed ID: 36376801
[TBL] [Abstract][Full Text] [Related]
39. Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
Huang J; Xu B; Liu Y; Huang J; Lu P; Ba Y; Wu L; Bai Y; Zhang S; Feng J; Cheng Y; Li J; Wen L; Yuan X; Ma C; Hu C; Fan Q; Wang X
Cancer Commun (Lond); 2019 Apr; 39(1):16. PubMed ID: 30940189
[TBL] [Abstract][Full Text] [Related]
40. Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy.
Okunaka M; Kotani D; Demachi K; Fujiwara H; Sakashita S; Yoshino T; Fujita T; Kojima T
Esophagus; 2022 Apr; 19(2):240-249. PubMed ID: 34611830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
